Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05022446 | The Impact of COVID-19 on Pulmonary Procedures | recruiting | — | 250 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05108519 | Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies | recruiting | — | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05111561 |
| Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
| recruiting |
| Phase 1 |
| 42 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 10, 2026 |
| clinicaltrials |
| NCT06237881 | A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06577194 | Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) | active not recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 | 42 | ModernaTX, Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07098988 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | recruiting | Phase 2 | 107 | CatalYm GmbHINDUSTRY | 7 | Aug 10, 2026 | clinicaltrials |
| NCT07728942 | SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 70 | Solve TherapeuticsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03997370 | Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | active not recruiting | Phase 1 | 350 | NRG OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT04280081 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321) | active not recruiting | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05502393 | A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 133 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05608148 | Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors | recruiting | Phase 1 | 61 | Kyushu UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05853367 | Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | active not recruiting | Phase 1 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT06630351 | Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness | enrolling by invitation | N/A | 80 | Mayo ClinicOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 | clinicaltrials |
| NCT07752953 | Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors(ZSNeo-DC-RWS) | recruiting | N/A | 100 | ZSky Biotech IncINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753499 | Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer | recruiting | N/A | 120 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753590 | A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 258 | BioRay Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT00777582 | Phase I Comparative Bioavailability Study | active not recruiting | Phase 1 | 197 | AstraZenecaINDUSTRY | 4 | Aug 6, 2026 | clinicaltrials |
| NCT01050504 | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer | recruiting | — | 1,500 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04089358 | Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study | active not recruiting | Phase 3 | 387 | Children's Oncology GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT04090619 | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers | active not recruiting | — | 192 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04386967 | OH2 Injection in Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | terminated | Phase 1 | 45 | Nuvectis Pharma, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT05600933 | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | enrolling by invitation | — | 1,200 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05944224 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 63 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 499 | Arvinas Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 220 | Strand Therapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04967833 | A Study of GC101 TIL in Advanced Solid Tumors (TR) | recruiting | Early Phase 1 | 20 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05087745 | A Clinical Study on TIL for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06089408 | Weighted Blanket Use to Reduce Anxiety in Oncology Patients | recruiting | N/A | 114 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations(SURF201) | active not recruiting | Phase 1 | 40 | Tyra Biosciences, IncINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06816108 | A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors | active not recruiting | Phase 1 | 35 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07256756 | A Study of GC203 TIL in Advanced Solid Tumors (NF) | recruiting | Phase 1 | 8 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07294872 | A Study of TIL in Advanced Solid Tumors (CZ) | not yet recruiting | Phase 1 | 30 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT04905914 | Study Of ATRN-119 In Patients With Advanced Solid Tumors(ABOYA-119) | completed | Phase 1 / Phase 2 | 43 | Aprea TherapeuticsINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05238792 | Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors(ATTACK) | recruiting | Phase 1 | 24 | Children's National Research InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05554341 | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05906537 | SKB410 for Injection in Solid Tumors | completed | Phase 1 | 38 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06380660 | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 298 | Acerand Therapeutics (Shanghai) LimitedINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06832982 | Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 | recruiting | Phase 1 | 66 | Shanghai Pushi Medical Science Co. LtdINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06880861 | Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers(IMPACT) | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07744763 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT01434316 | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 121 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02962661 | Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines | suspended | Phase 1 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 10, 2026source: clinicaltrials